![]() |
|
|
M Hagiwara, M Inagaki and H Hidaka
The interaction of the catalytic subunit of bovine cardiac muscle cAMP- dependent protein kinase with N-[2-(methylamino)ethyl]-5- isoquinolinesulfonamide (H-8), the most potent and selective inhibitor toward cyclic nucleotide-dependent protein kinases in the series of isoquinolinesulfonamide derivatives, was studied. The addition of H-8 protected the catalytic subunit of the enzyme in a dose-dependent manner from irreversible inactivation by the ATP analogue p- fluorosulfonylbenzoyl-5'-adenosine (FSBA). The inactivation followed pseudo-first order kinetics and H-8 reduced the steady state constant of inactivation (Ki) without any effect on the first order rate constant (K3). The quantitative binding of H-8 to the enzyme was measured under conditions of thermodynamic equilibrium using a gel filtration method. The catalytic subunit bound approximately 1 mol of drug/mol of protein with apparent half-maximal binding at 1.0 microM drug, whereas the enzyme irreversibly modified by FSBA did not bind the drug, confirming that the enzyme has no site for H-8 in the catalytic subunit other than the active site. The binding studies also showed that H-8 does not require divalent cations such as Mg2+ to bind to the catalytic subunit of the protein kinase. The binding of H-8 to the active site was characterized using FSBA and other affinity labeling reagents which have been postulated to modify residues at or near the active site of the catalytic subunit. H-8 protected the enzyme against inactivation by FSBA and Cibacron Blue F3GA but did not afford any protection against the covalent modification of 5,5'-dithiobis-(2- nitrobenzoic acid) (DTNB) and 7-chloro-4-nitro-2,1,3-benzoxadiazole (NBD-Cl), suggesting that the binding site of H-8 does not involve the gamma-subsite of the ATP binding site in the catalytic subunit, since DTNB and NBD-Cl are thought to modify the residues complementary to gamma-phosphate of the ATP molecules.
This article has been cited by other articles:
![]() |
M. Muraki, B. Ohkawara, T. Hosoya, H. Onogi, J. Koizumi, T. Koizumi, K. Sumi, J.-i. Yomoda, M. V. Murray, H. Kimura, et al. Manipulation of Alternative Splicing by a Newly Developed Inhibitor of Clks J. Biol. Chem., June 4, 2004; 279(23): 24246 - 24254. [Abstract] [Full Text] [PDF] |
||||
![]() |
I L P Beales and J Calam Inhibition of carbachol stimulated acid secretion by interleukin 1{beta} in rabbit parietal cells requires protein kinase C Gut, June 1, 2001; 48(6): 782 - 789. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. A. Volk, R. F. Husted, P. M. Snyder, and J. B. Stokes Kinase regulation of hENaC mediated through a region in the COOH-terminal portion of the alpha -subunit Am J Physiol Cell Physiol, May 1, 2000; 278(5): C1047 - C1054. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. Santicioli and C. A. Maggi Myogenic and Neurogenic Factors in the Control of Pyeloureteral Motility and Ureteral Peristalsis Pharmacol. Rev., December 1, 1998; 50(4): 683 - 722. [Abstract] [Full Text] [PDF] |
||||
![]() |
P. R. Young, M. M. McLaughlin, S. Kumar, S. Kassis, M. L. Doyle, D. McNulty, T. F. Gallagher, S. Fisher, P. C. McDonnell, S. A. Carr, et al. Pyridinyl Imidazole Inhibitors of p38 Mitogen-activated Protein Kinase Bind in the ATP Site J. Biol. Chem., May 2, 1997; 272(18): 12116 - 12121. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. A. Gebert, S.-H. Park, and D. J. Waxman Regulation of Signal Transducer and Activator of Transcription (STAT) 5b Activation by the Temporal Pattern of Growth Hormone Stimulation Mol. Endocrinol., April 1, 1997; 11(4): 400 - 414. [Abstract] [Full Text] |
||||
![]() |
R. A. Engh, A. Girod, V. Kinzel, R. Huber, and D. Bossemeyer Crystal Structures of Catalytic Subunit of cAMP-dependent Protein Kinase in Complex with Isoquinolinesulfonyl Protein Kinase Inhibitors H7, H8, and H89. STRUCTURAL IMPLICATIONS FOR SELECTIVITY J. Biol. Chem., October 18, 1996; 271(42): 26157 - 26164. [Abstract] [Full Text] [PDF] |
||||